JP2007504830A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504830A5
JP2007504830A5 JP2006526347A JP2006526347A JP2007504830A5 JP 2007504830 A5 JP2007504830 A5 JP 2007504830A5 JP 2006526347 A JP2006526347 A JP 2006526347A JP 2006526347 A JP2006526347 A JP 2006526347A JP 2007504830 A5 JP2007504830 A5 JP 2007504830A5
Authority
JP
Japan
Prior art keywords
compound according
compound
composition
oligonucleotide
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006526347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504830A (ja
JP4690324B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/029718 external-priority patent/WO2005023994A2/en
Publication of JP2007504830A publication Critical patent/JP2007504830A/ja
Publication of JP2007504830A5 publication Critical patent/JP2007504830A5/ja
Application granted granted Critical
Publication of JP4690324B2 publication Critical patent/JP4690324B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006526347A 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド Expired - Lifetime JP4690324B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50150903P 2003-09-09 2003-09-09
US60/501,509 2003-09-09
PCT/US2004/029718 WO2005023994A2 (en) 2003-09-09 2004-09-09 Modified oligonucleotides for telomerase inhibition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010286755A Division JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド

Publications (3)

Publication Number Publication Date
JP2007504830A JP2007504830A (ja) 2007-03-08
JP2007504830A5 true JP2007504830A5 (enExample) 2007-10-11
JP4690324B2 JP4690324B2 (ja) 2011-06-01

Family

ID=34273050

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2006526347A Expired - Lifetime JP4690324B2 (ja) 2003-09-09 2004-09-09 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2010286755A Expired - Lifetime JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Family Applications After (9)

Application Number Title Priority Date Filing Date
JP2010286755A Expired - Lifetime JP5923241B2 (ja) 2003-09-09 2010-12-22 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2011274595A Pending JP2012085648A (ja) 2003-09-09 2011-12-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2014087190A Pending JP2014158490A (ja) 2003-09-09 2014-04-21 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016014128A Expired - Lifetime JP6158966B2 (ja) 2003-09-09 2016-01-28 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2016137263A Withdrawn JP2016214248A (ja) 2003-09-09 2016-07-12 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2018025362A Expired - Lifetime JP6758335B2 (ja) 2003-09-09 2018-02-15 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2019131757A Withdrawn JP2019170400A (ja) 2003-09-09 2019-07-17 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2021110558A Withdrawn JP2021169466A (ja) 2003-09-09 2021-07-02 テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2023086871A Withdrawn JP2023099808A (ja) 2003-09-09 2023-05-26 テロメラーゼ阻害のための改変オリゴヌクレオチド

Country Status (19)

Country Link
US (8) US7494982B2 (enExample)
EP (3) EP1667522B1 (enExample)
JP (10) JP4690324B2 (enExample)
KR (3) KR101319388B1 (enExample)
CN (2) CN101293908B (enExample)
AU (2) AU2004271215B2 (enExample)
BR (1) BRPI0414222B8 (enExample)
CA (1) CA2536015C (enExample)
CY (2) CY1120113T1 (enExample)
DK (2) DK3342425T3 (enExample)
ES (2) ES2662196T3 (enExample)
HU (2) HUE036593T2 (enExample)
IL (1) IL173747A (enExample)
MX (1) MXPA06002660A (enExample)
NZ (1) NZ545516A (enExample)
PL (2) PL1667522T3 (enExample)
PT (2) PT3342425T (enExample)
SI (2) SI3342425T1 (enExample)
WO (1) WO2005023994A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3342425T1 (sl) 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
ATE503014T1 (de) 2003-11-04 2011-04-15 Geron Corp Rna-amidate und thioamidateur rnai
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
PT2101789E (pt) 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
AU2008212820B2 (en) 2007-02-09 2014-01-30 Northwestern University Particles for detecting intracellular targets
EP2134364B1 (en) 2007-03-09 2013-02-13 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
KR101625363B1 (ko) 2007-05-10 2016-05-30 애질런트 테크놀로지스, 인크. Rna 합성을 위한 티오카본-보호기
AU2008259907B2 (en) 2007-05-30 2014-12-04 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
TW200927177A (en) * 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
MX2011000100A (es) * 2008-07-02 2011-02-25 Enzon Pharmaceuticals Inc Antagonistas del acido ribonucleico que se dirigen a la proteina de choque termico 27.
EP2175023A1 (en) * 2008-07-31 2010-04-14 The University of Zurich Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA
PT3330383T (pt) 2008-10-17 2020-05-06 Geron Corp Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
DK2365803T3 (en) 2008-11-24 2018-01-22 Univ Northwestern POLYVALENT RNA NANOPARTICLE COMPOSITIONS
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
JP5866119B2 (ja) 2009-10-30 2016-02-17 ノースウェスタン ユニバーシティ 鋳型ナノ複合体
WO2011079290A1 (en) * 2009-12-24 2011-06-30 Northwestern University Oligonucleotide specific uptake of nanoconjugates
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
ES2656958T3 (es) 2011-03-28 2018-03-01 Geron Corporation Medición de la longitud de telómeros en muestras fijadas en formalina, embebidas en parafina (FFPE) por PCR cuantitativa
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP2014526517A (ja) 2011-09-14 2014-10-06 ノースウェスタン ユニバーシティ 血液脳関門を通過することができるナノ抱合体
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
US9228189B2 (en) 2012-10-26 2016-01-05 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
CA2887702C (en) 2012-10-26 2023-08-01 Geron Corporation C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders
EP2925889B1 (en) 2012-11-30 2018-09-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
IL280144B2 (en) 2012-12-07 2025-05-01 Geron Corp Use of telomerase inhibitors to treat bone marrow culture disorders and bone marrow culture tumors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PT2959005T (pt) 2013-02-22 2021-12-30 Univ Leland Stanford Junior Utilização médica relacionada com extensão de telómero
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
EP3868772A1 (en) 2013-09-30 2021-08-25 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016111530A1 (ko) * 2015-01-05 2016-07-14 권영아 루테리온을 이용한 암세포의 텔로머라아제 억제방법
CN113564168B (zh) * 2015-04-23 2024-10-25 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
EP3124609A1 (en) * 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutics oligonucleotides
EP3650546A1 (en) 2015-07-29 2020-05-13 IFOM Fondazione Istituto Firc di Oncologia Molecolare Therapeutic oligonucleotides
US20190249173A1 (en) * 2016-05-04 2019-08-15 Chandra Vargeese Methods and compositions of biologically active agents
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
CA3059321A1 (en) * 2017-04-20 2018-10-25 Synthena Ag Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
BR112020000410A2 (pt) * 2017-07-10 2020-07-14 Geron Corporation processo aprimorado para preparar imetelstat
WO2019023667A1 (en) 2017-07-28 2019-01-31 Janssen Biotech, Inc. METHODS OF TREATING MYELODYSPLASTIC SYNDROME
EP3790970A1 (en) 2018-05-07 2021-03-17 Alnylam Pharmaceuticals Inc. Extrahepatic delivery
EP3887537A4 (en) 2018-11-29 2023-04-12 Geron Corporation METHODS OF TREATMENT OF MYELODYSPLASTIC SYNDROME
JP7737667B2 (ja) * 2019-09-18 2025-09-11 国立大学法人東京科学大学 核酸複合体
AU2020375734B2 (en) * 2019-10-28 2026-04-09 Geron Corporation Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same
KR102861357B1 (ko) * 2019-10-28 2025-09-18 제론 코포레이션 비정질 고체 석신일화 3-(지방산 아미도)-2-하이드록시-1-(보호된 하이드록시)-프로판 염 및 이를 제조하는 방법
CN115776909A (zh) 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法
WO2022186350A1 (ja) * 2021-03-03 2022-09-09 国立大学法人東京大学 非環式スレオニノール核酸
WO2022199685A1 (zh) * 2021-03-25 2022-09-29 安沛治疗有限公司 具有延长的体内半衰期的核酸分子缀合物
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
WO2024257861A1 (ja) * 2023-06-16 2024-12-19 日産化学株式会社 脂質結合オリゴヌクレオチド又はその複合体

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) * 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DK0462145T3 (da) * 1989-03-07 1994-08-08 Genentech Inc Covalente konjugater mellem lipid og oligonucleotid
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
JPH05505941A (ja) * 1990-03-29 1993-09-02 ギリード サイエンシズ インコーポレーテッド オリゴヌクレオチド―輸送剤ジスルフィド結合体
US5420330A (en) * 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) * 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) * 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) * 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) * 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
ATE312175T1 (de) * 1993-10-18 2005-12-15 Inst Medical W & E Hall Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
EP0754242A4 (en) 1994-03-18 1997-06-11 Lynx Therapeutics Inc SYNTHESIS AND SUBSTANCE, HYBRIDIZATION AND NUCLEASE-RESISTANT PROPERTIES OF OLIGONUCLEOTID-N3'-m (7) P5'-PHOSPHORAMIDATE
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
GB9413035D0 (en) * 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
NZ289720A (en) 1994-07-07 1999-03-29 Geron Corp Nucleic acids coding for a telomerase, a ribonucleoprotein enzyme involved in telomere synthesis
EP0790965A1 (en) 1994-11-07 1997-08-27 HYBRIDON, Inc. Synthesis of ?35 s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
WO1997037691A1 (en) * 1996-04-10 1997-10-16 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) * 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
EP1379689B1 (en) 2001-03-23 2012-09-26 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
US20120329858A1 (en) 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
SI3342425T1 (sl) 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
CN100558739C (zh) 2004-07-02 2009-11-11 杰龙公司 合成被保护的3’-氨基核苷单体
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
PT2101789E (pt) 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro

Similar Documents

Publication Publication Date Title
JP2011092201A5 (enExample)
JP2023113843A5 (enExample)
JP6758335B2 (ja) テロメラーゼ阻害のための改変オリゴヌクレオチド
JP2022535911A5 (enExample)
US5872107A (en) Treatment of urogenital cancer with boron neutron capture therapy
JP2009524696A5 (enExample)
US6583122B2 (en) Nucleosides and oligonucleotides containing boron clusters
JP2021500025A5 (enExample)
JP2020022483A5 (enExample)
JP2020172488A (ja) Pd−l1発現低減用のオリゴヌクレオチド
JP2019525918A5 (enExample)
JP2021090458A5 (enExample)
JP2019511491A5 (enExample)
US20030119724A1 (en) Ligands to enhance cellular uptake of biomolecules
JP2022507282A5 (enExample)
JP2016502858A5 (enExample)
JP2015504650A5 (enExample)
TWI762732B (zh) 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
JP2013510561A5 (enExample)
HRP20110352T1 (hr) Antisens olinukleotidi za induciranje zaobilaženja egzona i postupci njihove upotrebe
JP2003523739A5 (enExample)
CN1211923A (zh) 增强生物分子的细胞摄取的配体
JP2009511034A5 (enExample)
JP2008513513A5 (enExample)
JP2021072862A5 (enExample)